Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
25 avr. 2022 16h42 HE
|
Revive Therapeutics Ltd.
TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19
18 avr. 2022 09h43 HE
|
Revive Therapeutics Ltd.
TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
11 avr. 2022 17h54 HE
|
Revive Therapeutics Ltd.
TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
29 mars 2022 08h45 HE
|
Revive Therapeutics Ltd.
Expected to seek DSMB approval to proceed with EUA application to the FDA in Q2-2022 Ongoing regulatory package activities for submission to international regulatory authorities for drug approvals ...
Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation
15 févr. 2022 16h26 HE
|
Revive Therapeutics Ltd.
TORONTO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
14 févr. 2022 06h00 HE
|
Revive Therapeutics Ltd.
Ethics Committee approval to proceed with Phase 3 clinical trial in Turkey13 clinical sites selected to date in Turkey TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive”...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
18 janv. 2022 21h02 HE
|
Revive Therapeutics Ltd.
701 subjects dosed to dateInitiating enrollment activities in Turkey as part of its clinical diversification plans to support global regulatory approvals On-track to complete enrollment in Q1-2022 and...
Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs
17 janv. 2022 08h17 HE
|
Revive Therapeutics Ltd.
IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs TORONTO, Jan. 17, 2022 ...
Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19
06 janv. 2022 16h24 HE
|
Revive Therapeutics Ltd.
Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment in Turkey by mid-FebruaryExpected to complete enrollment in Q1-2022 TORONTO, Jan. 06, 2022 ...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
29 déc. 2021 16h45 HE
|
Revive Therapeutics Ltd.
Screened approximately 700 subjects and expanding to Eastern Europe, including Turkey, as part of its clinical diversification plans to support global regulatory approvalsNo serious adverse events and...